Table of Contents

Namespaces

This section lists all of the namespaces that are defined in the original BEL script.

ADO
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/alzheimer-disease-ontology/alzheimer-disease-ontology-1.0.2.belns
BRCO
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/brain-region-ontology/brain-region-ontology-1.0.0.belns
CA
http://belief-ptsd.scai.fraunhofer.de/BeliefDashboard/dicten/namespaces/ca.belns
CBP
http://belief-ptsd.scai.fraunhofer.de/BeliefDashboard/dicten/namespaces/cbp.belns
CCHE
http://belief-ptsd.scai.fraunhofer.de/BeliefDashboard/dicten/namespaces/cche.belns
CHEBI
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/chebi/chebi-20170511.belns
DO
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170511.belns
GFAM
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc-gene-families/hgnc-gene-families-20170430.belns
GOBP
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go-biological-process/go-biological-process-20170511.belns
GOCC
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go-cellular-component/go-cellular-component-20170511.belns
HGNC
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc-human-genes/hgnc-human-genes-20170511.belns
HP
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20170724.belns
MESHC
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-chemicals/mesh-chemicals-20170511.belns
MESHCS
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-cell-structures/mesh-cell-structures-20170511.belns
MESHD
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-diseases/mesh-diseases-20170511.belns
MESHPP
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-processes/mesh-processes-20170511.belns
MGI
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mgi-mouse-genes/mgi-mouse-genes-20170511.belns
NIFT
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/imaging-ontology/imaging-ontology-1.0.0.belns
PMIBP
http://belief-demo.scai.fraunhofer.de/BeliefDashboard/dicten/namespaces/pmibp.belns
PMICHEM
http://belief-demo.scai.fraunhofer.de/BeliefDashboard/dicten/namespaces/pmichem.belns
PMICOMP
http://belief-demo.scai.fraunhofer.de/BeliefDashboard/dicten/namespaces/pmicomp.belns
PMIDIS
http://belief-demo.scai.fraunhofer.de/BeliefDashboard/dicten/namespaces/pmidis.belns
PMIPFAM
http://belief-demo.scai.fraunhofer.de/BeliefDashboard/dicten/namespaces/pmipfam.belns
PTS
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/neurodegeneration-pathways/neurodegeneration-pathways-1.0.0.belns
RGD
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/rgd-rat-genes/rgd-rat-genes-20170511.belns
SCOMP
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170511.belns
SFAM
https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170511.belns

Unused Namespaces 21

The source BEL script contained references to the following namespaces, but they were never used. It is suggested to delete their definitions from the BEL script to improve readability and parsing speed.

  • ADO
  • BRCO
  • CA
  • CBP
  • CCHE
  • GFAM
  • GOCC
  • HP
  • MESHC
  • MESHCS
  • MGI
  • NIFT
  • PMIBP
  • PMICHEM
  • PMICOMP
  • PMIDIS
  • PMIPFAM
  • PTS
  • RGD
  • SCOMP
  • SFAM

Annotations

This section lists all of the annotations that are defined in the original BEL script.

Keyword URL Stratify
Anatomy https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno View Stratified Summary
Cell https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno View Stratified Summary
CellLine https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno View Stratified Summary
CellStructure https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno View Stratified Summary
Confidence https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno View Stratified Summary
Disease https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno View Stratified Summary
Gender https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno View Stratified Summary
MeSHAnatomy https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno View Stratified Summary
MeSHDisease https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno View Stratified Summary
Species https://arty.scai.fraunhofer.de/artifactory/bel/annotation/species-taxonomy-id/species-taxonomy-id-20170511.belanno View Stratified Summary
Subgraph https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.1.belanno View Stratified Summary

Unused Annotations 25

The source BEL script contained references to the following annotations, but they were never used. It is suggested to delete their definitions from the BEL script to improve readability and parsing speed.

Note: this may be due to errors occurring in all statements with these annotations.

  • Anatomy
  • BRCO
  • Cell
  • CellStructure
  • Condition
  • Confidence
  • CultureType
  • Developmental_Phase__of_patient
  • DiseaseState
  • Duration_of_Chemical_Exposure
  • Encode_Feature_Types
  • Experimental_Group
  • FDASTATUS
  • Gender
  • KnockoutMice
  • MeSHDisease
  • NIFT
  • OxygenState
  • Patient
  • Race
  • StudyType
  • Subgraph
  • TherapyResistance
  • Transcriptionally_active_region
  • UserdefinedCellLine

Locally Defined Annotations 22

The source BEL script contained annotations defined as a list. Click each link to export the list definition as a BELANNO file that can hosted externally to promote re-usability and interoperability. After, you can replace the list definition in the source BEL with a SET ANNOTATION X AS URL "Y" definition.

Unused Locally Defined Annotations 21

The source BEL script contained the following list annotations, but no references to the following values. It is suggested to prune these values from the list definitions.

Note: this may be due to errors occurring in all statements with these annotations.

Annotation Values
BRCO
  • Striatum
  • Parietal_Lobe
  • Frontal_cortex
  • Hippocampus
  • Temporal_Lobe
  • Occipital_cortex
  • Cerebellum
Condition
  • Normal Healthy State
CultureType
  • Matrigel
  • plastic
Developmental_Phase__of_patient
  • Developmental stage
  • Old
  • Adult
  • Adolescence
  • Young
DiseaseState
  • Early-onset AD
  • Late-onset AD
  • Moderate AD
  • Pre-dementia
  • Mild AD
DiseaseType
  • Microsatellite-stable
  • wild-type RAS
Duration_of_Chemical_Exposure
  • Chronic
  • Subchronic
Encode_Feature_Types
  • Promoter
  • Enhancer
  • CTCF
  • TF binding site
  • Open chromatin
  • Promoter Flanking Region
Experimental_Group
  • Sedentary group
  • Physical exercised group
FDASTATUS
  • Phase 2
  • Phase 3
  • Phase 1
  • Phase 2/3
  • Approved
  • Inactive
  • Phase 4
  • Discontinued
KnockoutMice
  • IDE KO mice
  • INSR knockout mice
  • LID mice
  • GLP1 KO mice
  • IRS1 KO mice
  • KO Mapk8ip1
  • IGF1 KO mice
  • NIRKO mice
  • App transgenic
  • IRS2 KO mice
NIFT
  • Volumetric MRI
  • Positron Emission Tomography
OxygenState
  • normoxia
  • hypoxia
Patient
  • APOE e4 -ve
  • AD T2DM -ve
  • AD T2DM +ve
  • APOE e4 +ve
Race
  • Swedish
  • Colombian
  • White
  • silhouettes women
  • Chinese
  • non-Hispanic black
  • Black
  • Taiwanese
  • non-Hispanic white
  • Han Chinese in Taiwan
  • Han Chinese in Singapore
  • Hispanic
  • US women
  • Japanese
  • Caucasian
  • Italian
StudyType
  • in vivo
  • in vitro
TherapyResistance
  • oxaliplatin
  • anti-EGFR therapy
  • cisplatin
TisueType
  • cancerous
Transcriptionally_active_region
  • intron 1
  • 5 prime UTR
  • 3 prime UTR
  • exon 3
  • exon 41
UserdefinedCell
  • Beta cell
  • Astrocyte
  • Islets
UserdefinedCellLine
  • primary neuron
  • IDE APP transgenic
  • N2a695 cell
  • Neuroblastoma cell
  • App transgenic
  • 293APPwt
  • CHOAPPsw
  • primary cortical neuron
  • INS-1 cells
  • NT2N cells

Warning Statistics

Syntax Errors 8

Line BEL Message
128 composite(p(HGNC:FCGR2A sub(F,158,V)), a("Cetuximab")) causesNoChange bp("survival rate") General Parser Failure on line 128 at pos 24: composite(p(HGNC:FCGR2A sub(F,158,V)), a("Cetuximab")) causesNoChange bp("survival rate")
980 p(HGNC:FCGR3A, pmod(V,V,158)) positiveCorrelation bp(MESHPP:"Antibody-Dependent Cell Cytotoxicity") General Parser Failure on line 980 at pos 13: p(HGNC:FCGR3A, pmod(V,V,158)) positiveCorrelation bp(MESHPP:"Antibody-Dependent Cell Cytotoxicity")
981 p(HGNC:FCGR3A, pmod(V,F,158)) positiveCorrelation bp(MESHPP:"Antibody-Dependent Cell Cytotoxicity") General Parser Failure on line 981 at pos 13: p(HGNC:FCGR3A, pmod(V,F,158)) positiveCorrelation bp(MESHPP:"Antibody-Dependent Cell Cytotoxicity")
987 p(HGNC:FCGR3A, pmod(V,V,158)) positiveCorrelation bp("survival rate") General Parser Failure on line 987 at pos 13: p(HGNC:FCGR3A, pmod(V,V,158)) positiveCorrelation bp("survival rate")
1490 composite(a(CHEBI:"irinotecan"),bp(MESHPP:"Fasting")) negativeCorrelation path(MESHD:"Leukopenia") General Parser Failure on line 1490 at pos 31: composite(a(CHEBI:"irinotecan"),bp(MESHPP:"Fasting")) negativeCorrelation path(MESHD:"Leukopenia")
1504 composite(a(CHEBI:"irinotecan"),bp(MESHPP:"Fasting")) negativeCorrelation a(CHEBI:"SN-38") General Parser Failure on line 1504 at pos 31: composite(a(CHEBI:"irinotecan"),bp(MESHPP:"Fasting")) negativeCorrelation a(CHEBI:"SN-38")
1508 composite(a(CHEBI:"irinotecan"),bp(MESHPP:"Fasting")) negativeCorrelation a(CHEBI:"SN-38") General Parser Failure on line 1508 at pos 31: composite(a(CHEBI:"irinotecan"),bp(MESHPP:"Fasting")) negativeCorrelation a(CHEBI:"SN-38")
1512 composite(a(CHEBI:"irinotecan"),bp(MESHPP:"Fasting")) positiveCorrelation a(CHEBI:"SN-38") General Parser Failure on line 1512 at pos 31: composite(a(CHEBI:"irinotecan"),bp(MESHPP:"Fasting")) positiveCorrelation a(CHEBI:"SN-38")

All Parser Warnings 276

A faceted table view of all parser warnings can be viewed and exported from here.

Line BEL Message
120 p(HGNC:FCGR2A, sub(H,131,R)) -- a("Cetuximab related outcomes") [pos:34] "Cetuximab related outcomes" should be qualified with a valid namespace
121 p(HGNC:FCGR3A, sub(F,158,V)) -- a("Cetuximab related outcomes") [pos:34] "Cetuximab related outcomes" should be qualified with a valid namespace
127 composite(p(HGNC:FCGR2A), a("Cetuximab")) -> bp("survival rate") [pos:28] "Cetuximab" should be qualified with a valid namespace
128 composite(p(HGNC:FCGR2A sub(F,158,V)), a("Cetuximab")) causesNoChange bp("survival rate") General Parser Failure on line 128 at pos 24: composite(p(HGNC:FCGR2A sub(F,158,V)), a("Cetuximab")) causesNoChange bp("survival rate")
170 a("Cetuximab") =| p(HGNC:EGFR) [pos:2] "Cetuximab" should be qualified with a valid namespace
203 path(DO:"ovarian mucinous neoplasm") -| a("surviva rate") [pos:42] "surviva rate" should be qualified with a valid namespace
226 composite(a(CHEBI:"oxaliplatin"), a("Cetuximab")) -| path(MESHD:"Colorectal Neoplasms") [pos:36] "Cetuximab" should be qualified with a valid namespace
239 a("neoadjuvant") -> bp("survival rate") [pos:2] "neoadjuvant" should be qualified with a valid namespace
251 a("Bevacizumab") -| path(MESHD:"Neoplasms") [pos:2] "Bevacizumab" should be qualified with a valid namespace
259 composite(a(CHEBI:"lenalidomide"),a("Bevacizumab")) -| path(MESHD:"Neoplasms") [pos:36] "Bevacizumab" should be qualified with a valid namespace
260 composite(a(CHEBI:"lenalidomide"),a("Bevacizumab")) causesNoChange path("Drug Toxicity") [pos:36] "Bevacizumab" should be qualified with a valid namespace
270 a("FOLFIRI") hasMember list(a(CHEBI:"Calcium folinate"), a(CHEBI:"5-fluorouracil"), a(CHEBI:"irinotecan")) [pos:2] "FOLFIRI" should be qualified with a valid namespace
271 composite(a("Bevacizumab"),a("FOLFIRI")) -> bp("survival rate") [pos:12] "Bevacizumab" should be qualified with a valid namespace
283 a("FOLFOX") hasMember list(a(CHEBI:"Calcium folinate"), a(CHEBI:"5-fluorouracil"), a(CHEBI:"oxaliplatin")) [pos:2] "FOLFOX" should be qualified with a valid namespace
284 composite(a("Bevacizumab"),a("FOLFOX")) -> bp("survival rate") [pos:12] "Bevacizumab" should be qualified with a valid namespace
290 composite(a("Bevacizumab"),a("FOLFOX")) -| path(MESHD:"Colorectal Neoplasms") [pos:12] "Bevacizumab" should be qualified with a valid namespace
304 a("FOLFOX") -> a("Chemoresistance") [pos:2] "FOLFOX" should be qualified with a valid namespace
305 a("FOLFIRI") -> a("Chemoresistance") [pos:2] "FOLFIRI" should be qualified with a valid namespace
318 a("loaded liposomes") hasMember list(a(CHEBI:"Calcium folinate"), a(CHEBI:"oxaliplatin"), a(CHEBI:"5-fluorouracil"), a("5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrin")) [pos:2] "loaded liposomes" should be qualified with a valid namespace
320 a("loaded liposomes") -| bp(GOBP:"cell growth") [pos:2] "loaded liposomes" should be qualified with a valid namespace
325 a("drug encapsulation") -| a("Chemoresistance") [pos:2] "drug encapsulation" should be qualified with a valid namespace
337 g(HGNC:KRAS) biomarkerFor bp("anti-EGFR therapy resistance") [pos:29] "anti-EGFR therapy resistance" should be qualified with a valid namespace
338 g(HGNC:NRAS) biomarkerFor bp("anti-EGFR therapy resistance") [pos:29] "anti-EGFR therapy resistance" should be qualified with a valid namespace
343 p(HGNC:BRAF, sub(V,600,E)) biomarkerFor bp("patient prognosis") [pos:43] "patient prognosis" should be qualified with a valid namespace
348 g(HGNC:UGT1A1) biomarkerFor path("Drug Toxicity") [pos:33] "Drug Toxicity" should be qualified with a valid namespace
359 composite(a(CHEBI:"oxaliplatin"), a(CHEBI:"5-fluorouracil")) -> a("hematologic event") [pos:66] "hematologic event" should be qualified with a valid namespace
360 composite(a(CHEBI:"oxaliplatin"), a(CHEBI:"5-fluorouracil")) -> a("grade 3 hematologic toxicity") [pos:66] "grade 3 hematologic toxicity" should be qualified with a valid namespace
372 a("CapOx") hasMember list(a(CHEBI:"capecitabine"),a(CHEBI:"oxaliplatin")) [pos:2] "CapOx" should be qualified with a valid namespace
373 a("CapOx") -| path("neuropathy") [pos:2] "CapOx" should be qualified with a valid namespace
374 a("FOLFOX") -| path("neuropathy") [pos:2] "FOLFOX" should be qualified with a valid namespace
375 a("FOLFIRI") -| path("neuropathy") [pos:2] "FOLFIRI" should be qualified with a valid namespace
394 a("ruthenacycles") -| bp(GOBP:"cell growth") [pos:2] "ruthenacycles" should be qualified with a valid namespace
399 a("ruthenacycles") -> sec(p(HGNC:IFNG)) [pos:2] "ruthenacycles" should be qualified with a valid namespace
400 a("ruthenacycles") -| sec(p(HGNC:CCL5)) [pos:2] "ruthenacycles" should be qualified with a valid namespace
401 a("ruthenacycles") -| sec(p(HGNC:IGF1)) [pos:2] "ruthenacycles" should be qualified with a valid namespace
406 a("ruthenacycles") -- p(RPS21) [pos:2] "ruthenacycles" should be qualified with a valid namespace
407 a("ruthenacycles") -- bp(GOBP:"regulation of cytokine secretion") [pos:2] "ruthenacycles" should be qualified with a valid namespace
419 a("Bevacizumab") -> bp("survival rate") [pos:2] "Bevacizumab" should be qualified with a valid namespace
420 a("Aflibercept") -> bp("survival rate") [pos:2] "Aflibercept" should be qualified with a valid namespace
421 a(CHEBI:regorafenib) -> bp("survival rate") [pos:27] "survival rate" should be qualified with a valid namespace
422 a("Ramucirumab") -> bp("survival rate") [pos:2] "Ramucirumab" should be qualified with a valid namespace
427 a("Fruquintinib") -> bp("survival rate") #On PubChem [pos:2] "Fruquintinib" should be qualified with a valid namespace
428 a("Famitinib") -> bp("survival rate") #On PubChem [pos:2] "Famitinib" should be qualified with a valid namespace
429 a("nintedanib") -> bp("survival rate") #On PubChem [pos:2] "nintedanib" should be qualified with a valid namespace
434 a("VGX-100") =| p(HGNC:VEGFC)) [pos:2] "VGX-100" should be qualified with a valid namespace
435 composite(a("VGX-100"),a("bevacizumab")) =| p(HGNC:KDR) [pos:12] "VGX-100" should be qualified with a valid namespace
436 composite(a("VGX-100"),a("bevacizumab")) =| p(HGNC:FLT4) [pos:12] "VGX-100" should be qualified with a valid namespace
441 a("tanibirumab") =| p(HGNC:KDR) [pos:2] "tanibirumab" should be qualified with a valid namespace
442 a("vanucizumab") =| p(HGNC:VEGFA) [pos:2] "vanucizumab" should be qualified with a valid namespace
443 a("vanucizumab") =| p(HGNC:ANGPT2) [pos:2] "vanucizumab" should be qualified with a valid namespace
456 a("MM-1151") -| bp(GOBP:"cell growth") [pos:2] "MM-1151" should be qualified with a valid namespace
457 a("MM-1151") -| path(MESHD:"Colorectal Neoplasms") [pos:2] "MM-1151" should be qualified with a valid namespace
458 a("MM-1151") -| path(MESHD:"Neoplasm Invasiveness") [pos:2] "MM-1151" should be qualified with a valid namespace
459 a("MM-1151") -| a("Cetuximab resistance") [pos:2] "MM-1151" should be qualified with a valid namespace
472 a("Cetuximab") -| bp(GOBP:"epidermal growth factor receptor signaling pathway") [pos:2] "Cetuximab" should be qualified with a valid namespace
473 a("panitumumab") -| bp(GOBP:"epidermal growth factor receptor signaling pathway") [pos:2] "panitumumab" should be qualified with a valid namespace
475 a("Cetuximab") -- p(HGNC:KRAS) [pos:2] "Cetuximab" should be qualified with a valid namespace
476 a("panitumumab") -- p(HGNC:KRAS) [pos:2] "panitumumab" should be qualified with a valid namespace
492 composite(a(CHEBI:"5-fluorouracil"), a(CHEBI:"capecitabine")) -| a("mortality") [pos:67] "mortality" should be qualified with a valid namespace
497 composite(a(CHEBI:"5-fluorouracil"), a(CHEBI:"capecitabine")) causesNoChange a("mortality") [pos:79] "mortality" should be qualified with a valid namespace
508 p(HGNC:TP53) -> a("p53 antibody") [pos:18] "p53 antibody" should be qualified with a valid namespace
514 a("p53 antibody") biomarkerFor path(MESHD:"colorectal cancer") [pos:2] "p53 antibody" should be qualified with a valid namespace
520 a("FOLFOX"), a("Bevacizumab") -| a("CEA") [pos:2] "FOLFOX" should be qualified with a valid namespace
521 a("FOLFOX"), a("Bevacizumab") -| a("CA19-9") [pos:2] "FOLFOX" should be qualified with a valid namespace
527 a("FOLFOX"), a("Bevacizumab") -| a("p53 antibody") [pos:2] "FOLFOX" should be qualified with a valid namespace
532 a("p53 antibody") biomarkerFor path("tumor recurrence") [pos:2] "p53 antibody" should be qualified with a valid namespace
543 composite(a(CHEBI:"oxaliplatin"),a("traditional plant-based medicines")) -| path(MESHD:"Nausea") [pos:35] "traditional plant-based medicines" should be qualified with a valid namespace
544 composite(a(CHEBI:"oxaliplatin"),a("traditional plant-based medicines")) -| path(MESHD:"Vomoting") [pos:35] "traditional plant-based medicines" should be qualified with a valid namespace
556 a("Atractylodes macrocephala") -| path(MESHD:"Nausea") [pos:2] "Atractylodes macrocephala" should be qualified with a valid namespace
557 a("Atractylodes macrocephala") -| path(MESHD:"Vomiting") [pos:2] "Atractylodes macrocephala" should be qualified with a valid namespace
558 a("Atractylodes macrocephala") -> bp(GOBP:"antioxidant activity") [pos:2] "Atractylodes macrocephala" should be qualified with a valid namespace
559 a("Atractylodes macrocephala") -> bp("gastroprotective effects") [pos:2] "Atractylodes macrocephala" should be qualified with a valid namespace
560 a("Atractylodes macrocephala") -- bp(MESHPPP:"Gastrointestinal Motility") [pos:2] "Atractylodes macrocephala" should be qualified with a valid namespace
561 a("Poria cocos") -| path(MESHD:"Nausea") [pos:2] "Poria cocos" should be qualified with a valid namespace
562 a("Poria cocos") -| path(MESHD:"Vomiting") [pos:2] "Poria cocos" should be qualified with a valid namespace
563 a("Poria cocos") -> bp(GOBP:"antioxidant activity") [pos:2] "Poria cocos" should be qualified with a valid namespace
564 a("Poria cocos") -> bp("gastroprotective effects") [pos:2] "Poria cocos" should be qualified with a valid namespace
565 a("Poria cocos") -- bp(MESHPPP:"Gastrointestinal Motility") [pos:2] "Poria cocos" should be qualified with a valid namespace
566 a("Coix lacryma-jobi") -| path(MESHD:"Nausea") [pos:2] "Coix lacryma-jobi" should be qualified with a valid namespace
567 a("Coix lacryma-jobi") -| path(MESHD:"Vomiting") [pos:2] "Coix lacryma-jobi" should be qualified with a valid namespace
568 a("Coix lacryma-jobi") -> bp(GOBP:"antioxidant activity") [pos:2] "Coix lacryma-jobi" should be qualified with a valid namespace
569 a("Coix lacryma-jobi") -> bp("gastroprotective effects") [pos:2] "Coix lacryma-jobi" should be qualified with a valid namespace
570 a("Coix lacryma-jobi") -- bp(MESHPPP:"Gastrointestinal Motility") [pos:2] "Coix lacryma-jobi" should be qualified with a valid namespace
571 a("Astragalus membranaceus") -| path(MESHD:"Nausea") [pos:2] "Astragalus membranaceus" should be qualified with a valid namespace
572 a("Astragalus membranaceus") -| path(MESHD:"Vomiting") [pos:2] "Astragalus membranaceus" should be qualified with a valid namespace
573 a("Astragalus membranaceus") -> bp(GOBP:"antioxidant activity") [pos:2] "Astragalus membranaceus" should be qualified with a valid namespace
574 a("Astragalus membranaceus") -> bp("gastroprotective effects") [pos:2] "Astragalus membranaceus" should be qualified with a valid namespace
575 a("Astragalus membranaceus") -- bp(MESHPPP:"Gastrointestinal Motility") [pos:2] "Astragalus membranaceus" should be qualified with a valid namespace
576 a("Glycyrrhiza uralensis") -| path(MESHD:"Nausea") [pos:2] "Glycyrrhiza uralensis" should be qualified with a valid namespace
577 a("Glycyrrhiza uralensis") -| path(MESHD:"Vomiting") [pos:2] "Glycyrrhiza uralensis" should be qualified with a valid namespace
578 a("Glycyrrhiza uralensis") -> bp(GOBP:"antioxidant activity") [pos:2] "Glycyrrhiza uralensis" should be qualified with a valid namespace
579 a("Glycyrrhiza uralensis") -> bp("gastroprotective effects") [pos:2] "Glycyrrhiza uralensis" should be qualified with a valid namespace
580 a("Glycyrrhiza uralensis") -- bp(MESHPPP:"Gastrointestinal Motility") [pos:2] "Glycyrrhiza uralensis" should be qualified with a valid namespace
581 a("Panax ginseng") -| path(MESHD:"Nausea") [pos:2] "Panax ginseng" should be qualified with a valid namespace
582 a("Panax ginseng") -| path(MESHD:"Vomiting") [pos:2] "Panax ginseng" should be qualified with a valid namespace
583 a("Panax ginseng") -> bp(GOBP:"antioxidant activity") [pos:2] "Panax ginseng" should be qualified with a valid namespace
584 a("Panax ginseng") -> bp("gastroprotective effects") [pos:2] "Panax ginseng" should be qualified with a valid namespace
585 a("Panax ginseng") -- bp(MESHPPP:"Gastrointestinal Motility") [pos:2] "Panax ginseng" should be qualified with a valid namespace
602 a("Panitumumab") =| p(HGNC:EGFR) [pos:2] "Panitumumab" should be qualified with a valid namespace
603 composite(a("Panitumumab"),a("FOLFOXIRI")) -> path(MESHD:"Diarrhea") [pos:12] "Panitumumab" should be qualified with a valid namespace
604 composite(a("Panitumumab"),a("FOLFOXIRI")) -> path("rash") [pos:12] "Panitumumab" should be qualified with a valid namespace
610 composite(a("Panitumumab"),a("FOLFOXIRI"),p(HGNC:KRAS)) -| bp("survival rate") [pos:12] "Panitumumab" should be qualified with a valid namespace
611 composite(a("Panitumumab"),a("FOLFOXIRI"),p(HGNC:KRAS)) -| bp("survival rate") [pos:12] "Panitumumab" should be qualified with a valid namespace
628 a("bevacizumab") -| bp(GOBP:"Angiogenesis") [pos:2] "bevacizumab" should be qualified with a valid namespace
629 a("bevacizumab") =| p(HGNC:VEGFA) [pos:2] "bevacizumab" should be qualified with a valid namespace
630 a("aflibercept") -| bp(GOBP:"Angiogenesis") [pos:2] "aflibercept" should be qualified with a valid namespace
631 a("aflibercept") =| p(HGNC:VEGFA) [pos:2] "aflibercept" should be qualified with a valid namespace
632 a("ramucirumab") -| bp(GOBP:"Angiogenesis") [pos:2] "ramucirumab" should be qualified with a valid namespace
633 a("ramucirumab") =| p(HGNC:KDR) [pos:2] "ramucirumab" should be qualified with a valid namespace
649 composite(a("selective internal radiation therapy"), a("FOLFOX")) causesNoChange bp("survival rate") [pos:12] "selective internal radiation therapy" should be qualified with a valid namespace
650 composite(a("selective internal radiation therapy"), a("FOLFOX")) -| path(MESHD:"Disease Progression") [pos:12] "selective internal radiation therapy" should be qualified with a valid namespace
664 a(CHEBI:"yttrium atom") -> bp("survival rate") [pos:30] "survival rate" should be qualified with a valid namespace
665 composite(a(CHEBI:"yttrium atom"),a("chemotherapy")) -> bp("survival rate") [pos:36] "chemotherapy" should be qualified with a valid namespace
677 a("Cetuximab") -> bp("survival rate") [pos:2] "Cetuximab" should be qualified with a valid namespace
678 a("Bevacizumab") -> bp("survival rate") [pos:2] "Bevacizumab" should be qualified with a valid namespace
679 a("Panitumumab") -> bp("survival rate") [pos:2] "Panitumumab" should be qualified with a valid namespace
680 a("Panitumumab") =| p(HGNC:EGFR) [pos:2] "Panitumumab" should be qualified with a valid namespace
703 composite(a("Ramucirumab"),a("Chemotherapy")) -| bp(GOBP:"angiogenesis") [pos:12] "Ramucirumab" should be qualified with a valid namespace
704 composite(a("Ramucirumab"),a("Chemotherapy")) -| path(MESHD:"Colorectal Neoplasms") [pos:12] "Ramucirumab" should be qualified with a valid namespace
717 a(CETIRI) hasMember list(a("Cetuximab"), a(CHEBI:"irinotecan")) [pos:2] "CETIRI" should be qualified with a valid namespace
718 a(CHEBI:"LSM-1131") -| a("MET Pathway") [pos:25] "MET Pathway" should be qualified with a valid namespace
719 a("MET pathway") -> bp("anti-EGFR therapy resistance") [pos:2] "MET pathway" should be qualified with a valid namespace
728 a(CHEBI:"LSM-1131") -> path("Rash") [pos:28] "Rash" should be qualified with a valid namespace
741 a("Chemotherapy") -> path(MESHD:"Malnutrition") [pos:2] "Chemotherapy" should be qualified with a valid namespace
743 path(MESHD:"Malnutrition") -> path("Oncological outcomes") [pos:35] "Oncological outcomes" should be qualified with a valid namespace
751 path(MESHD:"Malnutrition") -- a("treatment tolerability") [pos:32] "treatment tolerability" should be qualified with a valid namespace
752 path(MESHD:"Malnutrition") -- path("Anastomotic Leakage") [pos:35] "Anastomotic Leakage" should be qualified with a valid namespace
753 path(MESHD:"Malnutrition") -- bp("survival rate") [pos:33] "survival rate" should be qualified with a valid namespace
772 a("biological therapy") -> bp("survival rate") [pos:2] "biological therapy" should be qualified with a valid namespace
773 a("Bevacizumab") -> bp("survival rate") [pos:2] "Bevacizumab" should be qualified with a valid namespace
785 a("Cetuximab") -> bp("survival rate") [pos:2] "Cetuximab" should be qualified with a valid namespace
796 a("Cetuximab") -> bp("survival rate") [pos:2] "Cetuximab" should be qualified with a valid namespace
800 a("Cetuximab") causesNoChange bp("survival rate") [pos:2] "Cetuximab" should be qualified with a valid namespace
807 a("Early Tumor Shrinkage") biomarkerFor a("Cetuximab efficacy") [pos:2] "Early Tumor Shrinkage" should be qualified with a valid namespace
818 composite(a("FOLFOXIRI"),a("bevacizumab")) -> bp("survival rate") [pos:12] "FOLFOXIRI" should be qualified with a valid namespace
835 a("panitumumab") =| p(HGNC:EGFR) [pos:2] "panitumumab" should be qualified with a valid namespace
836 a("cetuximab") =| p(HGNC:EGFR) [pos:2] "cetuximab" should be qualified with a valid namespace
837 g(HGNC:KRAS) biomarkerFor bp("panitumumab lack of response") [pos:29] "panitumumab lack of response" should be qualified with a valid namespace
838 g(HGNC:KRAS) biomarkerFor bp("cetuximab lack of response") [pos:29] "cetuximab lack of response" should be qualified with a valid namespace
846 a(RAS) hasMembers list(g(HGNC:KRAS),g(HGNC:NRAS)) [pos:2] "RAS" should be qualified with a valid namespace
847 g(HGNC:KRAS) biomarkerFor bp("survival rate") [pos:29] "survival rate" should be qualified with a valid namespace
848 g(HGNC:NRAS) biomarkerFor bp("survival rate") [pos:29] "survival rate" should be qualified with a valid namespace
860 a("(99m)Tc-duramycin") positiveCorrelation bp(GOBP:"cell death") [pos:2] "(99m)Tc-duramycin" should be qualified with a valid namespace
861 a("(99m)Tc-duramycin") positiveCorrelation p(HGNC:ANXA5) [pos:2] "(99m)Tc-duramycin" should be qualified with a valid namespace
862 a("(99m)Tc-duramycin") positiveCorrelation p(HGNC:CASP3) [pos:2] "(99m)Tc-duramycin" should be qualified with a valid namespace
863 a("(99m)Tc-duramycin") positiveCorrelation p(HGNC:CASP7) [pos:2] "(99m)Tc-duramycin" should be qualified with a valid namespace
869 a("(99m)Tc-duramycin") positiveCorrelation a(CHEBI:"irinotecan") [pos:2] "(99m)Tc-duramycin" should be qualified with a valid namespace
877 a("(99m)Tc-duramycin") positiveCorrelation a("Radiotherapy") [pos:2] "(99m)Tc-duramycin" should be qualified with a valid namespace
878 a("(99m)Tc-duramycin") positiveCorrelation deg(p(HGNC:CASP3)) [pos:2] "(99m)Tc-duramycin" should be qualified with a valid namespace
894 g(HGNC:ABCA9) biomarkerFor bp("Oxaliplatin treatment") [pos:31] "Oxaliplatin treatment" should be qualified with a valid namespace
896 g(HGNC:ABCB11) biomarkerFor bp("Oxaliplatin treatment") [pos:31] "Oxaliplatin treatment" should be qualified with a valid namespace
898 g(HGNC:ABCC10) biomarkerFor bp("Oxaliplatin treatment") [pos:31] "Oxaliplatin treatment" should be qualified with a valid namespace
900 g(HGNC:ATP1A1) biomarkerFor bp("Oxaliplatin treatment") [pos:31] "Oxaliplatin treatment" should be qualified with a valid namespace
902 g(HGNC:ATP1B2) biomarkerFor bp("Oxaliplatin treatment") [pos:31] "Oxaliplatin treatment" should be qualified with a valid namespace
904 g(HGNC:ATP8B3) biomarkerFor bp("Oxaliplatin treatment") [pos:31] "Oxaliplatin treatment" should be qualified with a valid namespace
906 g(HGNC:GSTM5) biomarkerFor bp("Oxaliplatin treatment") [pos:31] "Oxaliplatin treatment" should be qualified with a valid namespace
908 g(HGNC:GRHPR) biomarkerFor bp("Oxaliplatin treatment") [pos:31] "Oxaliplatin treatment" should be qualified with a valid namespace
934 composite(a(CHEBI:"lenalidomide"),a("FOLFOX")) -| path(MESHD:"Colorectal Neoplasms") [pos:36] "FOLFOX" should be qualified with a valid namespace
940 composite(a(CHEBI:"lenalidomide"),a("FOLFOX")) -> path(MESHD:"Neutropenia") [pos:36] "FOLFOX" should be qualified with a valid namespace
941 composite(a(CHEBI:"lenalidomide"),a("FOLFOX")) -> path(MESHD:"Thrombocytopenia") [pos:36] "FOLFOX" should be qualified with a valid namespace
942 composite(a(CHEBI:"lenalidomide"),a("FOLFOX")) -> path(MESHD:"Fatigue") [pos:36] "FOLFOX" should be qualified with a valid namespace
953 a("Cetuximab") =| p(HGNC:EGFR) [pos:2] "Cetuximab" should be qualified with a valid namespace
954 a("Cetuximab") -> bp(MESHPP:"Antibody-Dependent Cell Cytotoxicity") [pos:2] "Cetuximab" should be qualified with a valid namespace
959 a("Fcγ receptors") hasMembers list(p(HGNC:FCGBP),p(HGNC:FCGR1A),p(HGNC:FCGR1B),g(HGNC:FCGR1CP),p(HGNC:FCGR2A),p(HGNC:FCGR2B),p(HGNC:FCGR2C),p(HGNC:FCGR3A),p(HGNC:FCGR3B),p(HGNC:FCGRT)) [pos:2] "Fcγ receptors" should be qualified with a valid namespace
980 p(HGNC:FCGR3A, pmod(V,V,158)) positiveCorrelation bp(MESHPP:"Antibody-Dependent Cell Cytotoxicity") General Parser Failure on line 980 at pos 13: p(HGNC:FCGR3A, pmod(V,V,158)) positiveCorrelation bp(MESHPP:"Antibody-Dependent Cell Cytotoxicity")
981 p(HGNC:FCGR3A, pmod(V,F,158)) positiveCorrelation bp(MESHPP:"Antibody-Dependent Cell Cytotoxicity") General Parser Failure on line 981 at pos 13: p(HGNC:FCGR3A, pmod(V,F,158)) positiveCorrelation bp(MESHPP:"Antibody-Dependent Cell Cytotoxicity")
987 p(HGNC:FCGR3A, pmod(V,V,158)) positiveCorrelation bp("survival rate") General Parser Failure on line 987 at pos 13: p(HGNC:FCGR3A, pmod(V,V,158)) positiveCorrelation bp("survival rate")
992 a("Fcγ receptors") biomarkerFor a("Cetuximab Response") [pos:2] "Fcγ receptors" should be qualified with a valid namespace
1004 a("Bevacizumab") =| p(HGNC:VEGFA) [pos:2] "Bevacizumab" should be qualified with a valid namespace
1005 a("Bevacizumab") causesNoChange path(DO:"hemangioma of liver") [pos:2] "Bevacizumab" should be qualified with a valid namespace
1021 a("FOLFIRI") hasMembers list(a(CHEBI:"Calcium folinate"), a(CHEBI:"5-fluorouracil"), a(CHEBI:"irinotecan")) [pos:2] "FOLFIRI" should be qualified with a valid namespace
1022 a("FUPEP") hasMembers list(a(CHEBI:"Calcium folinate"), a(CHEBI:"5-fluorouracil"), a("PEP02")) [pos:2] "FUPEP" should be qualified with a valid namespace
1028 a("FUPEP") -- path(MESHD:"Diarrhea") [pos:2] "FUPEP" should be qualified with a valid namespace
1029 a("FUPEP") -- path(MESHD:"Neutropenia") [pos:2] "FUPEP" should be qualified with a valid namespace
1030 a("FUPEP") -- path(MESHD:"Mucositis") [pos:2] "FUPEP" should be qualified with a valid namespace
1031 a("FUPEP") -- path(MESHD:"Alopecia") [pos:2] "FUPEP" should be qualified with a valid namespace
1032 a("FOLFIRI") -- path(MESHD:"Diarrhea") [pos:2] "FOLFIRI" should be qualified with a valid namespace
1033 a("FOLFIRI") -- path(MESHD:"Neutropenia") [pos:2] "FOLFIRI" should be qualified with a valid namespace
1034 a("FOLFIRI") -- path(MESHD:"Mucositis") [pos:2] "FOLFIRI" should be qualified with a valid namespace
1035 a("FOLFIRI") -- path(MESHD:"Alopecia") [pos:2] "FOLFIRI" should be qualified with a valid namespace
1063 composite(a("necitumumab"),a("FOLFOX")) -- path(MESHD:"Neutropenia") [pos:12] "necitumumab" should be qualified with a valid namespace
1064 composite(a("necitumumab"),a("FOLFOX")) -- path(MESHD:"Asthenia") [pos:12] "necitumumab" should be qualified with a valid namespace
1065 composite(a("necitumumab"),a("FOLFOX")) -- path("Rash") [pos:12] "necitumumab" should be qualified with a valid namespace
1070 a("necitumumab") =| p(HGNC:EGFR) [pos:2] "necitumumab" should be qualified with a valid namespace
1071 composite(a("necitumumab"),a("FOLFOX")) -| path(MESHD:"Colorectal Neoplasms") [pos:12] "necitumumab" should be qualified with a valid namespace
1072 composite(a("necitumumab"),a("FOLFOX")) -> bp("survival rate") [pos:12] "necitumumab" should be qualified with a valid namespace
1086 a("Bevacizumab") =| p(HGNC:VEGFA) [pos:2] "Bevacizumab" should be qualified with a valid namespace
1087 a("Cetuximab") =| p(HGNC:EGFR) [pos:2] "Cetuximab" should be qualified with a valid namespace
1088 a("Panitumumab") =| p(HGNC:EGFR) [pos:2] "Panitumumab" should be qualified with a valid namespace
1094 composite(a("Bevacizumab"),a("Cetuximab")) causesNoChange path(MESHD:"Colorectal Neoplasms") [pos:12] "Bevacizumab" should be qualified with a valid namespace
1095 composite(a("Bevacizumab"),a("Panitumumab")) causesNoChange path(MESHD:"Colorectal Neoplasms") [pos:12] "Bevacizumab" should be qualified with a valid namespace
1110 a("Cetuximab") =| p(HGNC:EGFR) [pos:2] "Cetuximab" should be qualified with a valid namespace
1116 composite(a("Cetuximab"),a(CHEBI:"oxaliplatin")) -| p(HGNC:CASP3) [pos:12] "Cetuximab" should be qualified with a valid namespace
1117 composite(a("Cetuximab"),a(CHEBI:"oxaliplatin")) -| p(HGNC:CASP7) [pos:12] "Cetuximab" should be qualified with a valid namespace
1121 a(CHEBI:"oxaliplatin") -> a("reactive oxigen species") [pos:28] "reactive oxigen species" should be qualified with a valid namespace
1123 a(CHEBI:"oxaliplatin") -> bp("ROS dependent apoptotsis") [pos:29] "ROS dependent apoptotsis" should be qualified with a valid namespace
1124 a(CHEBI:"SN-38") -> a("reactive oxigen species") [pos:22] "reactive oxigen species" should be qualified with a valid namespace
1133 a("Cetuximab") -| p(HGNC:DUOX2) [pos:2] "Cetuximab" should be qualified with a valid namespace
1134 p(HGNC:DUOX2) -| bp("oxaliplatin cytotoxicity") [pos:20] "oxaliplatin cytotoxicity" should be qualified with a valid namespace
1135 a("Cetuximab") -> p(HGNC:MAPK14) [pos:2] "Cetuximab" should be qualified with a valid namespace
1136 p(HGNC:MAPK14) -| bp("oxaliplatin cytotoxicity") [pos:21] "oxaliplatin cytotoxicity" should be qualified with a valid namespace
1142 a("Cetuximab") -| p(HGNC:STAT1) [pos:2] "Cetuximab" should be qualified with a valid namespace
1143 a("Cetuximab") -| (p(HGNC:DUOX2) -> bp("ROS generation")) [pos:2] "Cetuximab" should be qualified with a valid namespace
1144 a("Cetuximab") -| (p(HGNC:MAPK14) -> bp(GOBP:"apoptotic process")) [pos:2] "Cetuximab" should be qualified with a valid namespace
1145 a("Cetuximab") -| a(CHEBI"oxaliplatin") [pos:2] "Cetuximab" should be qualified with a valid namespace
1170 a("Neoadjuvant concurrent chemoradiotherapy") -> path(MESHD:"Neutropenia") [pos:2] "Neoadjuvant concurrent chemoradiotherapy" should be qualified with a valid namespace
1185 a("irinotecan resistance") causesNoChange a("DEBIRI") [pos:2] "irinotecan resistance" should be qualified with a valid namespace
1186 a("DEBIRI") -| a("adverse events") [pos:2] "DEBIRI" should be qualified with a valid namespace
1198 a("Adjuvant FOLFOX chemotherapy") -> a("received dose intensity") [pos:2] "Adjuvant FOLFOX chemotherapy" should be qualified with a valid namespace
1211 p(HGNC:KRAS) biomarkerFor bp("therapy resistance") [pos:29] "therapy resistance" should be qualified with a valid namespace
1216 bp(GOBP:"regulation of Ras protein signal transduction") -> bp("cell growth") [pos:63] "cell growth" should be qualified with a valid namespace
1217 bp(GOBP:"MAPK cascade") -> bp("cell growth") [pos:30] "cell growth" should be qualified with a valid namespace
1222 composite(a(CHEBI:"selumetinib"),a("Cetuximab")) -> path("Rash") [pos:35] "Cetuximab" should be qualified with a valid namespace
1223 composite(a(CHEBI:"selumetinib"),a("Cetuximab")) -> path(MESHD:"Nausea") [pos:35] "Cetuximab" should be qualified with a valid namespace
1224 composite(a(CHEBI:"selumetinib"),a("Cetuximab")) -> path(MESHD:"Vomiting") [pos:35] "Cetuximab" should be qualified with a valid namespace
1225 composite(a(CHEBI:"selumetinib"),a("Cetuximab")) -> path(MESHD:"Diarrhea") [pos:35] "Cetuximab" should be qualified with a valid namespace
1226 composite(a(CHEBI:"selumetinib"),a("Cetuximab")) -> path(MESHD:"Fatigue") [pos:35] "Cetuximab" should be qualified with a valid namespace
1249 composite(a("Panitumumab"), a("FOLFOX")) -> bp("survival rate") [pos:12] "Panitumumab" should be qualified with a valid namespace
1261 composite(a("Bevacizumab"), a(CHEBI:"sorafenib")) -| path(MESHD:"Colorectal Neoplasms") [pos:12] "Bevacizumab" should be qualified with a valid namespace
1268 composite(a("Bevacizumab"), a(CHEBI:"sorafenib"), a("FOLFIRI")) -> a("disease stabilization") [pos:12] "Bevacizumab" should be qualified with a valid namespace
1281 composite(a("liver-specific intensive chemotherapy"),a("surgery")) -> bp("survival rate") [pos:12] "liver-specific intensive chemotherapy" should be qualified with a valid namespace
1302 composite(a("FOLFOX"), a("bevacizumab")) -| path(MESHD:"Colorectal Neoplasm") [pos:12] "FOLFOX" should be qualified with a valid namespace
1315 composite(a("FOLFIRI"),a("CT guided (125)I-seed implantation")) -> bp("survival rate") [pos:12] "FOLFIRI" should be qualified with a valid namespace
1331 a("early post operative chemotherapy") causesNoChange bp("survival rate") [pos:2] "early post operative chemotherapy" should be qualified with a valid namespace
1345 composite(a("Bevacizumab"),a(CHEBI:"capecitabine")) -> path(MESHD:"Hand-Foot Syndrome") [pos:12] "Bevacizumab" should be qualified with a valid namespace
1351 composite(a("Bevacizumab"),a(CHEBI:"capecitabine")) -| path(MESHD:"Colorectal Neoplasms") [pos:12] "Bevacizumab" should be qualified with a valid namespace
1364 a("Cetuximab") =| p(HGNC:EGFR) [pos:2] "Cetuximab" should be qualified with a valid namespace
1374 a("Cetuximab") causesNoChange bp(GOBP:"cell growth") [pos:2] "Cetuximab" should be qualified with a valid namespace
1379 a("Cetuximab") causesNoChange bp(GOBP:"cell growth") [pos:2] "Cetuximab" should be qualified with a valid namespace
1385 composite(a(CHEBI:"zoledronic acid"),a("Cetuximab")) =| bp(GOBP:"MAPK cascade") [pos:39] "Cetuximab" should be qualified with a valid namespace
1386 composite(a(CHEBI:"zoledronic acid"),a("Cetuximab")) =| bp(GOBP:"protein kinase B signaling") [pos:39] "Cetuximab" should be qualified with a valid namespace
1409 composite(a(CHEBI:"zoledronic acid"),a("Cetuximab")) =| path(MESHD:"Colorectal Neoplasms") [pos:39] "Cetuximab" should be qualified with a valid namespace
1410 composite(a(CHEBI:"zoledronic acid"),a("Cetuximab")) =| bp(GOBP:"cell growth") [pos:39] "Cetuximab" should be qualified with a valid namespace
1418 a("Peritoneal metastases") -| bp("survival rate") [pos:2] "Peritoneal metastases" should be qualified with a valid namespace
1427 a(CHEBI:"camptothecin") -> bp("survival rate") [pos:30] "survival rate" should be qualified with a valid namespace
1428 a(CHEBI:"oxaliplatin") -> bp("survival rate") [pos:29] "survival rate" should be qualified with a valid namespace
1442 a("XELOX") hasMembers list(a(CHEBI:"capecitabine"), a(CHEBI:"oxaliplatin")) [pos:2] "XELOX" should be qualified with a valid namespace
1449 composite(a("bevacizumab"),a("XELOX")) -> bp(GOBP:"transaminase activity") [pos:12] "bevacizumab" should be qualified with a valid namespace
1450 composite(a("bevacizumab"),a("XELOX")) -> path(MESHD:"Neutropenia") [pos:12] "bevacizumab" should be qualified with a valid namespace
1451 composite(a("bevacizumab"),a("XELOX")) -> path(MESHD:"Fatigue") [pos:12] "bevacizumab" should be qualified with a valid namespace
1452 composite(a("bevacizumab"),a("XELOX")) -> path(MESHD:"Anemia") [pos:12] "bevacizumab" should be qualified with a valid namespace
1453 composite(a("bevacizumab"),a("XELOX")) -> path(MESHD:"Neuropathy") [pos:12] "bevacizumab" should be qualified with a valid namespace
1459 composite(a("bevacizumab"),a("XELOX")) -> bp("survival rate") [pos:12] "bevacizumab" should be qualified with a valid namespace
1490 composite(a(CHEBI:"irinotecan"),bp(MESHPP:"Fasting")) negativeCorrelation path(MESHD:"Leukopenia") General Parser Failure on line 1490 at pos 31: composite(a(CHEBI:"irinotecan"),bp(MESHPP:"Fasting")) negativeCorrelation path(MESHD:"Leukopenia")
1504 composite(a(CHEBI:"irinotecan"),bp(MESHPP:"Fasting")) negativeCorrelation a(CHEBI:"SN-38") General Parser Failure on line 1504 at pos 31: composite(a(CHEBI:"irinotecan"),bp(MESHPP:"Fasting")) negativeCorrelation a(CHEBI:"SN-38")
1508 composite(a(CHEBI:"irinotecan"),bp(MESHPP:"Fasting")) negativeCorrelation a(CHEBI:"SN-38") General Parser Failure on line 1508 at pos 31: composite(a(CHEBI:"irinotecan"),bp(MESHPP:"Fasting")) negativeCorrelation a(CHEBI:"SN-38")
1512 composite(a(CHEBI:"irinotecan"),bp(MESHPP:"Fasting")) positiveCorrelation a(CHEBI:"SN-38") General Parser Failure on line 1512 at pos 31: composite(a(CHEBI:"irinotecan"),bp(MESHPP:"Fasting")) positiveCorrelation a(CHEBI:"SN-38")
1517 bp(MESHPP:"Fasting") -| a("side effects") [pos:26] "side effects" should be qualified with a valid namespace
1530 a("Cetuximab") =| p(HGNC:EGFR) [pos:2] "Cetuximab" should be qualified with a valid namespace
1531 a("Cetuximab") -> path(MESHD:"Acneiform Eruptions") [pos:2] "Cetuximab" should be qualified with a valid namespace
1542 p(HGNC:KDR) -- bp("survival rate") [pos:18] "survival rate" should be qualified with a valid namespace
1543 p(HGNC:KDR) negativeCorrelation bp("survival rate") [pos:35] "survival rate" should be qualified with a valid namespace
1548 composite(p(HGNC:KDR),a("chemotherapy"),a("bevacizumab")) -> bp("survival rate") [pos:24] "chemotherapy" should be qualified with a valid namespace
1563 a("resection of metastases") -> bp("survival rate") [pos:2] "resection of metastases" should be qualified with a valid namespace
1569 composite(a("bevacizumab"),a(CHEBI:"irinotecan")) -> bp("survival rate") [pos:12] "bevacizumab" should be qualified with a valid namespace
1586 a("Bevacizumab") -- path(MESHD:"Venous Thromoembolisms") [pos:2] "Bevacizumab" should be qualified with a valid namespace
1600 tscript(p(HGNC:AREG)) -- bp("survival rate") [pos:28] "survival rate" should be qualified with a valid namespace
1605 tscript(p(HGNC:EREG)) -- bp("survival rate") [pos:28] "survival rate" should be qualified with a valid namespace
1611 tscript(p(HGNC:EREG)) biomarkerFor bp("survival rate") [pos:38] "survival rate" should be qualified with a valid namespace
1631 composite(a("FOLFOX"),a("bevacizumab"),a("FOLFIRI")) -- path(MESHD:"Neutropenia") [pos:12] "FOLFOX" should be qualified with a valid namespace
1632 composite(a("FOLFOX"),a("bevacizumab"),a("FOLFIRI")) -- path(MESHD:"Leukopenia") [pos:12] "FOLFOX" should be qualified with a valid namespace
1633 composite(a("FOLFOX"),a("bevacizumab"),a("FOLFIRI")) -- path(MESHD:"Anorexia") [pos:12] "FOLFOX" should be qualified with a valid namespace
1634 composite(a("FOLFOX"),a("bevacizumab"),a("FOLFIRI")) -- path(MESHD:"Fatigue") [pos:12] "FOLFOX" should be qualified with a valid namespace
1635 composite(a("FOLFOX"),a("bevacizumab"),a("FOLFIRI")) -- path(MESHD:"Nausea") [pos:12] "FOLFOX" should be qualified with a valid namespace
1636 composite(a("FOLFOX"),a("bevacizumab"),a("FOLFIRI")) -- path(MESHD:"Vomiting") [pos:12] "FOLFOX" should be qualified with a valid namespace
1637 a("bevacizumab") -- path(MESHD:"Hypertension") [pos:2] "bevacizumab" should be qualified with a valid namespace
1638 a("bevacizumab") -- path(MESHD:"Thrombosis") [pos:2] "bevacizumab" should be qualified with a valid namespace
1644 composite(a("FOLFOX"),a("bevacizumab"),a("FOLFIRI")) -| path(MESHD:"Colorectal Neoplasms") [pos:12] "FOLFOX" should be qualified with a valid namespace
1645 composite(a("FOLFOX"),a("bevacizumab"),a("FOLFIRI")) -| path(MESHD:"Colorectal Neoplasms") [pos:12] "FOLFOX" should be qualified with a valid namespace
1678 p(HGNC:UBE3D) -| a("irinotecan sensitivity") [pos:19] "irinotecan sensitivity" should be qualified with a valid namespace
1679 p(HGNC:UBE3D) -| a("SN-38 sensitivity") [pos:19] "SN-38 sensitivity" should be qualified with a valid namespace
1680 p(HGNC:UBE3D) -| a("cetuximab sensitivity") [pos:19] "cetuximab sensitivity" should be qualified with a valid namespace
1682 p(HGNC:AKT1) -- a("irinotecan sensitivity") [pos:18] "irinotecan sensitivity" should be qualified with a valid namespace
1683 p(HGNC:AKT1) -- a("SN-38 sensitivity") [pos:18] "SN-38 sensitivity" should be qualified with a valid namespace
1684 p(HGNC:AKT1) -- a("cetuximab sensitivity") [pos:18] "cetuximab sensitivity" should be qualified with a valid namespace
1692 p(HGNC:UBE3D) biomarkerFor bp("Chemoresistance") [pos:30] "Chemoresistance" should be qualified with a valid namespace

Top Warnings

Error Frequency
[pos:2] "Cetuximab" should be qualified with a valid namespace 22
[pos:12] "FOLFOX" should be qualified with a valid namespace 9
[pos:12] "Bevacizumab" should be qualified with a valid namespace 9
[pos:2] "Bevacizumab" should be qualified with a valid namespace 8
[pos:31] "Oxaliplatin treatment" should be qualified with a valid namespace 8
[pos:2] "FOLFIRI" should be qualified with a valid namespace 8
[pos:12] "bevacizumab" should be qualified with a valid namespace 7
[pos:2] "(99m)Tc-duramycin" should be qualified with a valid namespace 7
[pos:2] "ruthenacycles" should be qualified with a valid namespace 6
[pos:2] "FOLFOX" should be qualified with a valid namespace 6
[pos:12] "necitumumab" should be qualified with a valid namespace 5
[pos:35] "Cetuximab" should be qualified with a valid namespace 5
[pos:12] "Panitumumab" should be qualified with a valid namespace 5
[pos:2] "Atractylodes macrocephala" should be qualified with a valid namespace 5
[pos:2] "Glycyrrhiza uralensis" should be qualified with a valid namespace 5
[pos:2] "Panax ginseng" should be qualified with a valid namespace 5
[pos:2] "Poria cocos" should be qualified with a valid namespace 5
[pos:2] "Coix lacryma-jobi" should be qualified with a valid namespace 5
[pos:2] "Astragalus membranaceus" should be qualified with a valid namespace 5
[pos:2] "FUPEP" should be qualified with a valid namespace 5

Naked Names 81

Names referenced without a namespace are antithetical to reproducible science and data integration practices. The list of "naked names" can be downloaded here for further use with tools to help find the appropriate names.

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of the open source project, PyBEL. Please feel free to contact us here to give us feedback or report any issues.